Product Development


<div class="articleContainer">
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">What clinical holds and pauses mean for COVID-19 countermeasure timelines</h1><h2 class="title-bottom" doc-editable="title" data-component-id="doc-1ef7l34r60"></h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By Lauren Martz, Senior Editor</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div></div>


Johnson & Johnson

Eli Lilly and Co.

AstraZeneca plc

Infectious

Coronavirus disease (COVID-19)

cov19pol

cov19count

AZD1222 (ChAdOx1 nCoV-19)

bamlanivimab, LY-CoV555 (LY3819253)

What clinical holds and pauses mean for COVID-19 countermeasure timelines

Three high-profile COVID-19 trials are now temporarily halted after potential safety issues were flagged by independent Data and Safety Monitoring Boards, but whether sponsors will need to wait for

Featured Analysis

Articles

Current Editions

Data Graphics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

China Healthcare Summit

Bio€quity Europe

Events

My Workspace

Company Overview

Management

Editorial & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Trial

Subscribe

Advertising & Sponsorship

Career Opportunities

Customer Resource Center

Contact

Home

<br/><center><span style="font-size:1.75rem;font-weight:500;">Access This Article</span></center>

Paywall Not Entitled Title

Request a Trial

Purchase This Article

<center><span style="font-weight:300;">[Subscribers Log in]{{login}}</span></center>

Paywall Sub log in